Tag: Verzenio

Eli Lilly with promising oncology presentations at ESMO
September 29, 2019 Off

Eli Lilly with promising oncology presentations at ESMO

By Dino Mustafić

Eli Lilly on Sunday presented data from results of testing its two oncology products; for registration of oral selpercatinib monotherapy, for the treatment of RET-altered thyroid cancers, and its abemaciclib branded Verzenio in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer

FDA OK’s Eli Lilly’s breast cancer drug
September 29, 2017 Off

FDA OK’s Eli Lilly’s breast cancer drug

By Dino Mustafić

The U.S. Food and Drug Administration has approved  Eli Lilly’s Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy).